Weekly Endocrinology Research Analysis
This week’s endocrinology literature highlights translational gains across cardiometabolic therapeutics, glucose-monitoring–driven care, and regenerative biomaterials. A prespecified SELECT analysis showed semaglutide reduces MACE and improves fatty liver indices in obese patients at high fibrosis risk. CGM-based randomized-trial data (GRADE substudy) reinforce that incretin-based add-ons minimize hypoglycemia and glycemic variability compared with sulfonylurea or basal insulin, supporting CGM-i
Summary
This week’s endocrinology literature highlights translational gains across cardiometabolic therapeutics, glucose-monitoring–driven care, and regenerative biomaterials. A prespecified SELECT analysis showed semaglutide reduces MACE and improves fatty liver indices in obese patients at high fibrosis risk. CGM-based randomized-trial data (GRADE substudy) reinforce that incretin-based add-ons minimize hypoglycemia and glycemic variability compared with sulfonylurea or basal insulin, supporting CGM-informed therapy choice. A pH-responsive ion-releasing hydrogel advanced from animal models to a pilot clinical signal for markedly improved diabetic wound healing, indicating a promising translational device.
Selected Articles
1. Semaglutide on liver fibrosis and heart outcomes in patients at high risk of liver fibrosis: a prespecified analysis of the SELECT randomized trial.
In a prespecified secondary analysis of the SELECT randomized trial (104-week follow-up), semaglutide reduced major adverse cardiovascular events in obese adults without diabetes who were at increased risk for liver fibrosis by FIB-4 criteria, and produced greater reductions in fatty liver index vs placebo. Effects were consistent across FIB-4 thresholds, supporting cardiometabolic and hepatic benefit in this subgroup.
Impact: Extends high-quality RCT evidence that GLP-1RA therapy confers cardiovascular benefit to obese patients at elevated liver-fibrosis risk and links metabolic liver improvement to reduced MACE, informing cross-disciplinary treatment prioritization.
Clinical Implications: Consider semaglutide for obese patients with elevated noninvasive fibrosis scores (e.g., FIB-4) even without diabetes when integrated cardiometabolic–hepatology benefit is a priority; validate fibrosis via imaging/biopsy when clinically indicated and monitor hepatic and cardiovascular endpoints.
Key Findings
- Prespecified SELECT subgroup analysis showed MACE reduction by 26% in patients with FIB-4 ≥1.3 (HR 0.74) and consistent benefit across age-specific FIB-4 thresholds.
- Semaglutide produced a 28% greater decrease in fatty liver index versus placebo over 104 weeks.
- Trend toward larger MACE reduction in the highest FIB-4 stratum (FIB-4 >2.67) though not statistically conclusive.
2. Comparison of the Continuous Glucose Monitoring Profiles of Four Glucose-Lowering Medications in the GRADE Randomized Trial.
A masked CGM substudy of the randomized GRADE trial (n=1,080) found liraglutide and sitagliptin achieved the highest time-in-range (70–180 mg/dL), lowest time-below-range, and lowest glycemic variability (%CV), while glimepiride produced the worst CGM profile with the most hypoglycemia and daytime events. These results emphasize CGM metrics as actionable endpoints for drug selection.
Impact: One of the first head-to-head CGM comparisons across four commonly used add-on therapies, linking drug classes to real-world glycemic variability and hypoglycemia outcomes beyond HbA1c.
Clinical Implications: Prefer incretin-based add-ons (liraglutide, sitagliptin) to maximize TIR and minimize hypoglycemia/variability when adding therapy to metformin; incorporate CGM metrics (TIR, TBR, %CV) into routine decision-making, especially for patients at high hypoglycemia risk.
Key Findings
- Liraglutide and sitagliptin had the highest TIR70–180 and lowest TBR<70 and %CV among four add-on therapies.
- Glimepiride had the lowest TIR, highest variability, and most CGM-derived hypoglycemic events, including daytime hypoglycemia.
- Incretin therapies best met consensus CGM targets (e.g., TBR<54 <1% and combined TIR>70% with TBR<70 <4%).
3. Self-regulating hydrogel for diabetic wound healing: From animal models to a pilot clinical study.
A pH-responsive GPP@ZnBG hydrogel released antibacterial zinc early under alkaline microenvironments and later released Zn/Ca/silicate ions to promote angiogenesis and tissue repair. It improved neovascularization, collagen deposition, and wound closure in diabetic mice; a small uncontrolled pilot clinical application reported a 94.57% relative wound-area reduction at 4 weeks with no adverse events.
Impact: Demonstrates a mechanism-driven, stimulus-responsive biomaterial validated across preclinical models with an early clinical signal for a high unmet need (chronic diabetic wounds), suggesting a scalable therapeutic platform pending randomized trials.
Clinical Implications: If confirmed in randomized controlled trials, topical self-regulating ion-releasing hydrogels could become an adjunct to standard wound care to reduce infection and accelerate repair, potentially lowering amputation rates; meanwhile, RCTs with controls and longer follow-up are needed before clinical adoption.
Key Findings
- GPP@ZnBG hydrogel released zinc early under alkaline conditions for antibacterial effect, then released Zn/Ca/silicate to support angiogenesis and repair.
- In diabetic mice, hydrogel treatment improved neovascularization, collagen deposition, and wound closure.
- Single-cell RNA-seq indicated modulation of fibroblast NF-κB signaling to reduce maladaptive inflammation.
- A pilot clinical application reported a 94.57% relative wound-area reduction at 4 weeks with no reported adverse events.